Press releases

02 Jul 2019

BC Partners to Acquire Synthon International Holding B.V.

read more
25 Jan 2018

Synthon’s [vic-]trastuzumab duocarmazine (SYD985) granted FDA Fast Track designation for pre-treated HER2-positive metastatic breast cancer

read more
15 Mar 2017

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

read more
02 Mar 2017

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

read more
12 Dec 2016

MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC

read more
18 May 2016

Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

read more
28 Sep 2015

Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985

read more
25 Nov 2014

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

read more
06 May 2014

Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

read more
02 Apr 2014

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC

read more